Skip to main content
Clinical Trials/NCT01763541
NCT01763541
Withdrawn
Early Phase 1

Gonadal Steroid Regulation of the Natriuretic Peptide System

Massachusetts General Hospital1 site in 1 countryJune 2014

Overview

Phase
Early Phase 1
Intervention
leuprolide acetate
Conditions
Hypertension
Sponsor
Massachusetts General Hospital
Locations
1
Primary Endpoint
NP levels in men with testosterone patch and low-salt diet
Status
Withdrawn
Last Updated
8 years ago

Overview

Brief Summary

There is gender dimorphism in cardiovascular risk, with men at higher risk than women. However, the fundamental basis for the protective effect of female sex remains unclear. Recent data implicate the natriuretic peptide (NP) system as an important determinant of blood pressure. Also, NP levels are twice as high in women of reproductive age than in men, and gonadal steroids are important determinants of circulating NPs. These are the marked, but poorly understood differences in the NP status between men and women. The investigators hypothesize that gonadal steroids regulate NP release, specifically that testosterone inhibits and estrogen activates the NP axis, leading to differences in both resting NP levels and dynamic responses of the NP, RAAS, and kidneys to acute and chronic salt loading. Understanding the basis for gender differences in NP function should provide important insights regarding mechanisms underlying hypertension in men versus women.

Registry
clinicaltrials.gov
Start Date
June 2014
End Date
February 2016
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Karen Klahr Miller, MD

Director, Neuroendocrine Research Program in Women's Health

Massachusetts General Hospital

Eligibility Criteria

Inclusion Criteria

  • 18-40 years old
  • no history of hypertension
  • normal BMI
  • Male: normal testosterone and free testosterone levels
  • Female: regular menses, negative pregnancy test, no sex steroid therapy \>/=3 mos

Exclusion Criteria

  • on hypertensives, diuretics, or insulin
  • with diabetes mellitus
  • estimated creatinine clearance \<60 ml/min
  • prior cardiovascular, liver or renal disease
  • history of hormonally-responsive cancer
  • elevated liver function test (LFTs)
  • atrial fibrillation
  • abnormal sodium or potassium levels
  • taking medications that directly impact the endocrine system (exogenous hormones, steroids, etc.)
  • taking medications that indirectly impact the endocrine system (SSRIs, opioids, finasteride, etc.)

Arms & Interventions

Testosterone

To determine the effect of testosterone on the NP responses to acute and chronic salt loading. One testosterone patch (Androderm 5 mg) applied to each male subject each day for 14 days. Intervention: Leuprolide acetate and anastrozole

Intervention: leuprolide acetate

Testosterone

To determine the effect of testosterone on the NP responses to acute and chronic salt loading. One testosterone patch (Androderm 5 mg) applied to each male subject each day for 14 days. Intervention: Leuprolide acetate and anastrozole

Intervention: Anastrozole

Estradiol

To determine the effect of estradiol on the NP responses to acute and chronic salt loading. Two estradiol patches (Vivelle Dot 0.1mg) will be applied to each female subject twice-a-week for 2 weeks. Intervention: leuprolide acetate

Intervention: leuprolide acetate

Outcomes

Primary Outcomes

NP levels in men with testosterone patch and low-salt diet

Time Frame: At day 7 of week of testosterone administration with low-salt diet

B-type natriuretic peptide (BNP), Atrial natriuretic peptide (ANP), amino-terminal brain natiuretic peptide (N-BNP), amino-terminal atrial natiuretic peptide (N-ANP), cyclic guanosine monophosphate (cGMP)

NP levels in men with testosterone patch and high-salt diet

Time Frame: At day 7 of week of testosterone administration with high-salt diet

B-type natriuretic peptide (BNP), Atrial natriuretic peptide (ANP), amino-terminal brain natiuretic peptide (N-BNP), amino-terminal atrial natiuretic peptide (N-ANP), cyclic guanosine monophosphate (cGMP)

NP levels in women with estradiol patch and low-salt diet

Time Frame: At day 7 of week of estradiol administration with low-salt diet

B-type natriuretic peptide (BNP), Atrial natriuretic peptide (ANP), amino-terminal brain natiuretic peptide (N-BNP), amino-terminal atrial natiuretic peptide (N-ANP), cyclic guanosine monophosphate (cGMP)

NP levels in women with estradiol patch and high-salt diet

Time Frame: At day 7 of week of estradiol administration with high-salt diet

B-type natriuretic peptide (BNP), Atrial natriuretic peptide (ANP), amino-terminal brain natiuretic peptide (N-BNP), amino-terminal atrial natiuretic peptide (N-ANP), cyclic guanosine monophosphate (cGMP)

NP levels in men with placebo patch and low-salt diet

Time Frame: At day 7 of week of placebo administration with low-salt diet

B-type natriuretic peptide (BNP), Atrial natriuretic peptide (ANP), amino-terminal brain natiuretic peptide (N-BNP), amino-terminal atrial natiuretic peptide (N-ANP), cyclic guanosine monophosphate (cGMP)

NP levels in men with placebo patch and high-salt diet

Time Frame: At day 7 of week of placebo administration with high-salt diet

B-type natriuretic peptide (BNP), Atrial natriuretic peptide (ANP), amino-terminal brain natiuretic peptide (N-BNP), amino-terminal atrial natiuretic peptide (N-ANP), cyclic guanosine monophosphate (cGMP)

NP levels in women with placebo patch and low-salt diet

Time Frame: At day 7 of week of placebo administration with low-salt diet

B-type natriuretic peptide (BNP), Atrial natriuretic peptide (ANP), amino-terminal brain natiuretic peptide (N-BNP), amino-terminal atrial natiuretic peptide (N-ANP), cyclic guanosine monophosphate (cGMP)

NP levels in women with placebo patch and high-salt diet

Time Frame: At day 7 of week of placebo administration with high-salt diet

B-type natriuretic peptide (BNP), Atrial natriuretic peptide (ANP), amino-terminal brain natiuretic peptide (N-BNP), amino-terminal atrial natiuretic peptide (N-ANP), cyclic guanosine monophosphate (cGMP)

Secondary Outcomes

  • Plasma Renin Activity (PRA) levels in women on estradiol on low-salt diet(At day 7 of week of estradiol administration on low-salt diet)
  • Aldosterone levels in men with testosterone on low-salt diet(At day 7 of week of testosterone administration on low-salt diet)
  • Plasma Renin Activity (PRA) levels in women on estradiol on high-salt diet(At days 6 and 7 of week of estradiol administration on high-salt diet)
  • Plasma Renin Activity (PRA) levels in women on placebo on low-salt diet(At day 7 of week of placebo administration on low-salt diet)
  • Plasma Renin Activity (PRA) levels in women on placebo on high-salt diet(At days 6 and 7 of week of placebo administration on high-salt diet)
  • Plasma Renin Activity (PRA) levels in men on testosterone on low-salt diet(At day 7 of week of testosterone administration on low-salt diet)
  • Plasma Renin Activity (PRA) levels in men on testosterone on high-salt diet(At days 6 and 7 of week of testosterone administration on high-salt diet)
  • Plasma Renin Activity (PRA) levels in men on placebo on low-salt diet(At day 7 of week of placebo administration on low-salt diet)
  • Plasma Renin Activity (PRA) levels in men on placebo on high-salt diet(At days 6 and 7 of week of placebo administration on high-salt diet)
  • Aldosterone levels in men on testosterone on high-salt diet(At days 6 and 7 of week of testosterone administration on high-salt diet)
  • Aldosterone levels in men on placebo on high-salt diet(At days 6 and 7 of week of placebo administration on high-salt diet)
  • Aldosterone levels in men on placebo on low-salt diet(At day 7 of week of placebo administration on low-salt diet)
  • Aldosterone levels in women on estradiol on high-salt diet(At days 6 and 7 of week of estradiol administration on high-salt diet)
  • Aldosterone levels in women on estradiol on low-salt diet(At day 7 of week of estradiol administration on low-salt diet)
  • Aldosterone levels in women on placebo on high-salt diet(At days 6 and 7 of week of placebo administration on high-salt diet)
  • Aldosterone levels in women on placebo on low-salt diet(At day 7 of week of placebo administration on low-salt diet)
  • Urinary sodium concentration in women on estradiol on high-salt diet(0, 60, and 120 minute of saline infusion on morning of day 7 of estradiol administration on high-salt diet)
  • Urinary sodium concentration in women on placebo on high-salt diet(0, 60, and 120 minute of saline infusion on morning of day 7 of placebo administration on high-salt diet)
  • Urinary sodium concentration in men on testosterone on high-salt diet(0, 60, and 120 minute of saline infusion on morning of day 7 of testosterone administration on high-salt diet)
  • Urinary sodium concentration in men on placebo on high-salt diet(0, 60, and 120 minute of saline infusion on morning of day 7 of placebo administration on high-salt diet)

Study Sites (1)

Loading locations...

Similar Trials